Medifast Q2 revenue falls 37%

Medifast

04/08/2025 21:14

Overview

Medifast Q2 2025 revenue falls 37% yr/yr but beats analyst expectations, per LSEG data

Net income for Q2 2025 at $2.5 mln, aided by LifeMD stock gain

Co focuses on coach growth and productivity initiatives amid revenue decline

Outlook

Medifast expects Q3 2025 revenue between $70 mln and $90 mln

Company anticipates Q3 2025 diluted EPS between ($0.60) and $0.00

Result Drivers

COACH DECLINE - Revenue fell due to a 32.7% decrease in active earning OPTAVIA coaches, driven by client acquisition challenges

CLIENT ACQUISITION - Continued pressure on client acquisition affected average revenue per coach, reflecting broader market challenges

GLP-1 IMPACT - Rapid adoption of GLP-1 medications for weight loss contributed to revenue decline

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$105.56 mln
$96.10 mln (1 Analyst)
Q2 EPS
$0.22
Q2 Net Income
$2.48 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the food processing peer group is "buy."

Wall Street's median 12-month price target for Medifast Inc is $15.00, about 8.3% above its August 1 closing price of $13.75

Press Release: ID:nBw75hr03a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)